Thank you, Mr. Chair, and thank you to our guests here today.
We had rather interesting testimony from the departments the other day. In their deck and presentation and in another document that was provided as a briefing, they were saying that on one hand, the proposals in C-393 would enter us into a trade challenge and maybe threaten investment in Canada. There would be a series of other problems. At the same time, it wouldn't work.
It didn't make any sense. They were making both claims.
One of the points I wanted you to maybe comment on is that they say here:
There is no evidence that changing CAMR will result in more developing countries using the regime to import drugs from Canada rather than continuing to purchase low-cost drugs from other sources.
We were just talking a little bit about that with Mr. Braid. I'd like you to talk a little bit about the Apotex situation. The reality is that we have generic companies in this country that are world-class successful and would increase jobs if production actually increased. Can you comment on that, please?